Floatz logo

Hydroxyurea

Mild Cognitive Impairment

Jaime Daniel MondragonSmall moleculePhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

99 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Sra-333
Helse Stavanger HF
Phase 4BBB
Metformin
Fudan University
Phase 4BB
Ginkgo Biloba Extract
Hanyang University
Phase 4BB
Ginkgo Biloba
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4BB
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 2/3BB

View all 50 →

Same molecule, other indications

Hydroxyurea is also rated in:

beta-thalassemia majorDormant
BBB
Indicative ·
77 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
71 / 100
View asset →
thalassemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →